Thank you for the opportunity to review this protocol for a cluster randomized trial of iCCM in rural Mali. This is an important study as very little experimental research has been undertaken to examine the effectiveness of iCCM. I have some comments related to the intervention and design that I feel would strengthen the utility of the study.
• The methods seem to indicate that there will be longitudinal follow up of the same cohort of women enrolled at baseline at the 12, 24 and 36 month points. Why was this approach chosen over repeat cross sectional surveys of the population at the three time points? Or is the entire population of women 15-49 in the 137 clusters going to be included?
• 137 clusters appears like a huge number for a cluster trial. Would it not be more efficient to have fewer, larger clusters? Have the authors considered the implications of loss of clusters on the analysis.
• What is the expected sample size of women to be enrolled in each cluster?
• I believe that this study would be strengthened by having a control arm where there is no iCCM provided only removal of user fees at PHC facilities. This would answer the question whether iCCM is effective in reducing mortality and increasing access to care compared to free routine PHC services.
• Who will be providing the CHW salaries the local government or the researchers? If it is the researchers what will happen once the study is complete. Similarly with the removal of user fees. Will this continue after completion of the study?
• Was any consideration given to the ratio of CHWs to population required for the ProCCM arm? The feasibility to achieve the expected workload appears questionable in this arm if each CHW covers a population of 700 with a fertility rate of 6.3 in Mali it seems unrealistic for them to undertaken maternal, newborn, child and general adult care, follow up within 24 hours after referral; 24,48 and 72 hours after a malaria diagnosis, monitor pregnant women every 2 weeks and weekly in the final month, conduct postnatal care within 24,48 hours, 5 days and once a week until 48 days after delivery as well as administering contraceptives. The study would need to carefully document whether this workload at the current ratio of workers to population is feasible.
• Page 12 states that the study is measuring maternal mortality. Why is maternal mortality being collected if this is not a primary or secondary outcome of the study and the intervention is not aimed at reducing maternal mortality.
• The proposed intervention at health facilities does not appear to have been designed with sustainability in mind-equipping each PHC with 5 laptops and expecting the staff to duplicate their workload by entering into the electronic EMS as well as their regular facility registers. This appears to be an undue burden on health workers that could in fact compromise care.
Minor comments:
• Figure 1 , the map of the study area was missing from the submission.
• The abstract states a baseline survey will be conducted but in fact this has already occurred in 2016.
• The study is receiving funding from the Johnson and Johnson foundation. The authors should consider and declare any potential conflict of interest by accepting funding from a commercial company that produces pharmaceuticals relevant to the interventions provided in the study.
REVIEWER
Nicholas P Oliphant 1) University of Western Cape, South Africa 2) The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland REVIEW RETURNED 18-Dec-2018
GENERAL COMMENTS
This cluster RCT will make an important contribution to knowledge about iCCM and will be highly relevant to a wide audience, including policy makers, managers, health workers, donors, researchers and the general public. The manuscript describing the trial protocol is of high quality. I recommend minor revisions (see attached file).
In this review page number refer to page numbers on the upper left corner of manuscript. Lines refer to the line numbers provided on the left edge of the manuscript. Abstract Page 2: In the methods section of the abstract, summarize how risk of bias will be mitigated (to be detailed in the methods section). If all of the risks of bias cannot be included in the methods section of the abstract (due to word count) select the most important ones to summarize. For instance the study is unblinded as noted in the methods section of the full article. Page 6, line 22: You indicate the RCT is -to test a proactive model of CHW service delivery‖. As per the comment above for the abstract, please use a standard wording to describe the intervention e.g. -proactive case detection. Consider using the same language in your description on page 6, lines 29-42 as you provided on page 8, lines 6-13. Page 6, lines 26-28: For your control you indicate -compared to the same set of comprehensive services delivered via the standard iCCM model relying on patient-initiated care-seeking‖. Per the supplementary material I understand that the CHWs in the control arm are also getting additional interventions/support compared to what CHWs implementing iCCM typically get in the Mali context (e.g. reinforcement of facility-based care, removal of user fees, regular supervision -CHW supervision in Mali is known to be irregular, enhanced training etc.) The only difference between the intervention arm and the control arm is the use of the active case detection approach. Please clarify that this is the only difference between the arms. Also clarify that the standard of iCCM in the control arm is not the exact same as the standard of iCCM as implemented in Mali (e.g. the standard in Mali includes user fees and has not necessarily entailed systems strengthening at health facility level, and the frequency and modality of supervision differs from that of the control arm). Page 6, line 31: Consider acknowledging the broader terminology of -lay health workers‖ (per the review by Lewin et al) since iCCM may be delivered by other types of lay health workers, not only -CHWs‖ as such. Consider acknowledging this and then where relevant indicate that your focus here is on the implementation of iCCM by CHWs as defined in Mali. Methods Page 7, line 9: Please include ProCCM parentheses for study aim #1 as you have done for study aims #2 and #3. Page 7, lines 9-25: Again please clarify that intervention being tested is -door-to-door proactive case detection‖. Page 8, line 6: The reference [49] does not appear to be included in the references. Should this be reference [22] instead? Page 9, line 29: The reference [49] does not appear to be included in the references. Should this be reference [22] instead? Page 10, line 36. The word -by‖ is missing in the sentence. Page 14. Analysis plan. Please indicate whether you will check for balance on outcomes at baseline (i.e. to ensure randomization achieved balance on outcomes) and how you will handle imbalances (if any) on outcomes at baseline. Page 18, line 29: You describe the intervention as -a proactive case detection workflow‖. As noted above please use a standard description for consistency e.g. -door-to-door proactive case detection‖.
In the methods section, include further information on how risk of bias will be mitigated. Cochrane EPOC provides guidance for risk of bias for RCTs at https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uplo ads/Resources-forauthors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.p df 1) mitigation of selection bias by how randomization schemes will be generated; 2) mitigation of selection bias by how allocation will be concealed (whether allocation of clusters or controls will be done independently) 3) how performance bias will be mitigated by whether participants and personnel (i.e. CHWs/others) will be blinded to allocation 4) how performance bias will be mitigated by whether assessors will be blinded to allocation 5) how attrition bias will be mitigated by mitigating / managing incomplete outcome data 6) how reporting bias will be mitigated by mitigating selective reporting 7) how you will mitigate risk of bias from imbalance in baseline outcomes (including any procedures needed in analysis to adjust for unforeseen imbalances if baseline has not been conducted) 8) how you will mitigate risk of bias from imbalance in baseline characteristics (including any procedures needed in analysis to adjust for unforeseen imbalances if baseline has not been conducted) 9) how you will mitigate risk of bias from contamination
Intervention

REVIEWER
Dr Yannan Jiang University of Auckland, New Zealand REVIEW RETURNED 02-Feb-2019
GENERAL COMMENTS
This study protocol reported a cluster randomised controlled trial in rural Mali that aims to test the efficacy of proactive community case management intervention in reducing under-five mortality, compared to conventional CHW service delivery at a community health post only. The study is being conducted in 7 of 22 health catchment areas within the Bankass health district in eastern Mali. Trial data are collected from three sources: household surveys administered to all eligible women at baseline, and 12, 24 and 36 months after the intervention; the community health worker mobile application data; and primary health centre (PHC) facility data. The paper is well written, and has generally followed the reporting guidelines.
In a cluster randomised trial, both cluster and individual levels data are collected. It is therefore important to describe them separately in details. For randomisation, distance to PHC was considered in stratification (1-5 kilometres vs. >5 kilometres) and supplementary analyses (<5 kilometres vs. 5 kilometres or more). Should the strata be consistent? How was the additional stratum defined for all villages where the PHC was located? How many strata in total were used in randomisation? Note that stratification variables should usually be included as covariates in the primary model.
How was the per protocol analysis defined on the primary and secondary outcomes? Most studies have a number of secondary variables for efficacy; however, there has been no common consent about their roles in clinical trials. Multiple hypothesis testing will be adjusted on all secondary outcomes using the Bonferroni correction, which is not common for a two-arm trial with one primary outcome. Can the authors discuss more on the role and weight of secondary outcomes in the trial?
The sample size calculation considered each cluster as an observation and the cluster-level outcome was defined as the underfive mortality rate per person-years at risk. A negative binomial model was used to simulate the number of deaths, assuming a three-year prospective study with 10% attrition and a coefficient of variation of 0.29. A total of 137 clusters (69 intervention and 68 control) will detect a relative difference of 25% between groups with ~80% power after 36 months. How is this effect size compared to clinical significance?
In analysis plan, the effect of intervention on the primary outcome will be tested using a Poisson regression model which is under different assumption from the initial model used in sample size calculation. The primary analysis will control for age in months, which suggests individual-level data analysis rather than treating each cluster as an observation. Note that the outcome variable will be defined differently at cluster and individual levels, and the cluster effect must be taken into account in hierarchical model. Please provide full details on the regression models used in the ITT and PP analyses, and the list of covariates (cluster or individual) that will be adjusted in the model.
A data safety and monitoring board (DSMB) will provide oversight throughout the trial. Please give more information on the roles and responsibilities of the DSMB. Will interim analysis be conducted?
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Reviewer Name: Tanya Doherty
Institution and Country: South African Medical Research Council
Please state any competing interests or state ‗None declared': none Please leave your comments for the authors below
Thank you for the opportunity to review this protocol for a cluster randomized trial of iCCM in rural Mali. This is an important study as very little experimental research has been undertaken to examine the effectiveness of iCCM. I have some comments related to the intervention and design that I feel would strengthen the utility of the study.
• It would help readers if the authors could provide background information on the under-5 mortality rate in the study area. This is important to assess the expected difference on which the sample size is based. The expected 25% difference in incidence rate of under 5 mortality appears very ambitious.
In Mopti, the region of the study site, the under-five mortality rate (U5MR) was estimated as 111 deaths per 1,000 live births for the ten-year period preceding the survey during the 2012-2013 DHS (95% CI 88-135). This is higher than the national U5MR of 104 deaths per 1,000 live births during the equivalent period. Since the 2013 DHS, Intermittent Preventive Therapy in children (IPTc) for malaria has been rolled out across the region. As IPTc is associated with a risk ratio of all-cause under-five mortality of 0.66 in areas of seasonal transmission of malaria (33), we estimate that baseline underfive mortality rate in the area of the intervention will be 111*0.66=72.6/1000. This text is added to the paper on page 11, Sample size.
Our study is powered for a relative difference of 25%, or an absolute difference of 0.75%, between the two study arms. The projected small absolute difference was intended to be conservative, but still large enough to have a population health significance and merit consideration of national and global policy change.
•
The methods seem to indicate that there will be longitudinal follow up of the same cohort of women enrolled at baseline at the 12, 24 and 36 month points. Why was this approach chosen over repeat cross sectional surveys of the population at the three time points? Or is the entire population of women 15-49 in the 137 clusters going to be included?
The entire population of (consenting) women 15-49 in the 137 clusters is included, in order to reach the sample size. Clarification to this point has been added under the inclusion criteria subsection on page 12.
In terms of power to detect the effects of interest, the power is increased by increasing the number of clusters. There were extensive sample size calculations to determine a sufficient number of clusters, and 137 provided over 80% power to find significant differences. Although it may be cheaper to have fewer but larger clusters, in the long run this does not translate into real savings because this is a scientific study and the eventual success of the study depends on having sufficient numbers of clusters to have a large power (i.e., high probability of finding a significant effect if there is a true strong effect).
We are not clear on your comment about -the implications of loss of clusters on the analysis‖. If that was meant to be -the implications of lots of clusters on the analysis‖, our previous paragraph answers that issue. If you are worried about clusters not being able to complete their interventions and being lost from the analysis, we have thought about this. The supplement gives details on monitoring and quality assurance plans to minimize the possibility of poor adherence of the intervention (see -CHW supervision‖ and -CHW reporting‖ sections of the Supplement).
According to national estimates for 2016, the seven health catchment areas covering 137 clusters of villages and hamlets will have a population of 103,848 inhabitants. Estimating that 22% of this population consists of women of reproductive age, the number of women of reproductive age in those health catchment areas is estimated at 22,847, with an average of 167 women per cluster. The average number of women ages 15 to 49 per cluster is now noted on page 11.
Thank you for this recommendation. Unfortunately, we are now past the design stage, as the trial has started.
• Who will be providing the CHW salaries the local government or the researchers? If it is the researchers what will happen once the study is complete. Similarly, with the removal of user fees. Will this continue after completion of the study?
Thank you for this question. The nongovernmental organization implementing the intervention will be paying the CHW salaries and removal of user fees. The organization has no plans to stop intervening in the study area after the end of the study period. The intervention may be modified based on the findings of the study. Importantly, the President of the Republic of Mali recently announced a healthcare reform that included a commitment to scale-up a paid, professionalized cadre of CHWs over the next four years, and to remove user fees for all children under five, pregnant women, family planning, the elderly, and dialysis services.
The ratio of CHWs to population was designed to be consistent across both arms of the study, and in line with Mali's national policy, which recommends a ratio of 1:700 in the study area (as described in the paper on page 8). We are conducting a process evaluation of this intervention as well, in order to document implementation fidelity, mechanisms of change, including CHW and patient's experiences with and perspective of the intervention, and contextual factors influencing or influenced by the intervention.
Given the inclusion of maternal health services in CHW scope of services, the intervention may reduce maternal mortality via improved access to contraception, and antenatal, perinatal, and postnatal care. However, the study is not sufficiently powered to detect a difference in this outcome. For this reason, the maternal mortality ratio was not included among the secondary outcomes in the first version of this paper. However, we appreciate the reviewer's comment and have included it among the secondary outcomes with the caveat that we will assessed if we have sufficient and robust data to do so.
The proposed intervention at health facilities does not appear to have been designed with sustainability in mind-equipping each PHC with 5 laptops and expecting the staff to duplicate their workload by entering into the electronic EMS as well as their regular facility registers. This appears to be an undue burden on health workers that could in fact compromise care.
Indeed, we had initially intended to replace the facility registers with an EMR system to avoid the dual entry burden; however, we later learned that the government mandates that the facility registers continue to be filled out by hand as the government's primary source of PHC data. This added burden on health workers is a concern for us. After some months of EMR deployment, we noticed a data completeness problem in the EMR system. We hired short-term data entry personnel to back-enter facility register data into the EMR. Since then, we provide PHC providers an extra financial compensation to complete the EMR data entry outside of their healthcare provision working hours. The government is now actively interested in exploring potential for digitization of its national health system in the context of its national health care reform, so the policy situation around this issue is rapidly evolving.
• Figure 1 , the map of the study area was missing from the submission. This is now uploaded as a separate document.
The abstract states a baseline survey will be conducted but in fact this has already occurred in 2016. This paper intentionally uses the future tense throughout as it is a trial protocol.
The study is receiving funding from the Johnson and Johnson foundation. The authors should consider and declare any potential conflict of interest by accepting funding from a commercial company that produces pharmaceuticals relevant to the interventions provided in the study.
We appreciate the reviewer's vigilance and attention to this point. We have considered this and have determined that there is no conflict of interest.
The intervention tests a health care delivery approach, proactive case detection, and does not assess any specific pharmaceutical medications, devices, or other products. The intervention team uses the government supply chain and procurement systems wherever possible, and when additional procurement is needed, uses competitive bidding processes. Low cost generic medications and products are preferred whenever available. Ultimately, the study tests two different workflows for CHWs, and does not test pharmaceutical products. Therefore, there is no conflict of interest to declare. This cluster RCT will make an important contribution to knowledge about iCCM and will be highly relevant to a wide audience, including policy makers, managers, health workers, donors, researchers and the general public. The manuscript describing the trial protocol is of high quality. I recommend minor revisions.
Prepared by Nicholas Oliphant 12 December 2018
In this review page number refer to page numbers on the upper left corner of manuscript. Lines refer to the line numbers provided on the left edge of the manuscript.
Abstract
Page 2: In the methods section of the abstract, summarize how risk of bias will be mitigated (to be detailed in the methods section). If all of the risks of bias cannot be included in the methods section of the abstract (due to word count) select the most important ones to summarize. For instance, the study is unblinded as noted in the methods section of the full article.
We added that the study is unblinded to the abstract on page 2. We added additional information throughout the methods section of the paper to describe how we minimize risk of bias-details below where Reviewer 2 comments on the Methods section.
Page 2, line 36: You use the phrase -a proactive community case management (ProCCM) intervention‖ to describe the intervention but then later in line 44 you describe it as -community-based proactive case detection‖. Later in the background section (line 22) you use the phrase -proactive model of CHW service delivery‖. The clearest description is probably on page 8, line 10-12: -door-todoor proactive case detection by CHWs, including doorstep care and home-based follow-up‖. Please use this as a standard wording for the intervention throughout the text e.g. -door-to-door proactive case detection‖. And since the RCT is testing only the effect of proactive case detection, make this clear using the standard wording.
Great recommendation. This has been done throughout.
Page 2, line 45: Please provide more clarity on what is meant by a -health post‖. There is some description in the supplementary online material but it remains unclear. Clarify that the -health post‖ is not a health center/facility. Clarify this throughout. Please indicate whether service delivery exclusively from a fixed health post is the standard/usual way CHWs deliver services in Mali.
Throughout the paper, we have changed this to -community health site‖ which is the language used in the Mali national CHW plan and better describes something that is not a facility. It is clear in the Methods under Study design on page 8 that this is a CHW community health post and that this is the usual way CHWs deliver serviced in Mali; further clarification provided under Intervention on page 8.
Page 2, line 52: You indicate repeat surveys will be conducted at baseline, 12, 24 and 36 months. You indicate a life table tracking all births and deaths occurring in the 59 months prior to enrollment through the 36 months of follow up. Clarify which outcomes be measured and reported i.e. which specific mortality outcomes, what other outcomes will be measured and reported (if word count prevents a full listing in the abstract at least provide a short line on the primary outcome/s).
Indeed, as word count prevents a full listing of secondary outcomes, a line was added about the primary outcome at the end of the methods section of the abstract (page 2). Studies by Kalyango (2) and Mubiru were included among references for the effectiveness of iCCM to improve access to care and treatment adherence (page 5, paragraph 2). Studies by Boone, Mukanga and Yansaneh were included among the references for mixed results of iCCM on health outcomes (page 5, paragraph 3).
Page 5, line 22: You indicate the RCT is -to test a proactive model of CHW service delivery‖. As per the comment above for the abstract, please use a standard wording to describe the intervention e.g. -proactive case detection. Consider using the same language in your description on page 6, lines 29-42 as you provided on page 8, lines 6-13.
New paragraph on page 6 taking into account this and the comment directly below.
Page 6, lines 26-28: For your control you indicate -compared to the same set of comprehensive services delivered via the standard iCCM model relying on patient-initiated care-seeking‖. Per the supplementary material I understand that the CHWs in the control arm are also getting additional interventions/support compared to what CHWs implementing iCCM typically get in the Mali context (e.g. reinforcement of facility-based care, removal of user fees, regular supervision -CHW supervision in Mali is known to be irregular, enhanced training etc.) The only difference between the intervention arm and the control arm is the use of the active case detection approach. Please clarify that this is the only difference between the arms. Also clarify that the standard of iCCM in the control arm is not the exact same as the standard of iCCM as implemented in Mali (e.g. the standard in Mali includes user fees and has not necessarily entailed systems strengthening at health facility level, and the frequency and modality of supervision differs from that of the control arm).
New paragraph on page 6 taking into account this and the comment directly above.
Page 6, line 31: Consider acknowledging the broader terminology of -lay health workers‖ (per the review by Lewin et al) since iCCM may be delivered by other types of lay health workers, not only -CHWs‖ as such. Consider acknowledging this and then where relevant indicate that your focus here is on the implementation of iCCM by CHWs as defined in Mali.
Throughout the paper we refer to community health workers in the broad sense (i.e., according to Lewin et al -lay health worker‖) since there is no universally accepted terminology for this cadre of health worker. We anticipate lessons learned from this study will be relevant to iCCM program design, implementation and scale up regardless of the specific profile of the community health worker (though the study, and Mali's national policy, adheres to recent WHO recommendations that Community Health Workers should be paid for their work). We have added detail to Table 1 to indicate what elements of the CHW package of services offered in this intervention (both arms) are consistent with the Mali national policy for CHWs.
Methods
Page 7, line 9: Please include ProCCM parentheses for study aim #1 as you have done for study aims #2 and #3.
Not necessary after taking into account the comment directly below.
Page 7, lines 9-25: Again please clarify that intervention being tested is -door-to-door proactive case detection‖.
Changed here and throughout. This has been fixed. Page 14. Analysis plan. Please indicate whether you will check for balance on outcomes at baseline (i.e. to ensure randomization achieved balance on outcomes) and how you will handle imbalances (if any) on outcomes at baseline.
Though we find no baseline difference in the under-five mortality rate across arms (primary endpoint) as estimated using the under-five mortality estimation procedures used by the Demographic and Health Surveys (https://www.dhsprogram.com/pubs/pdf/DHSG1/Guide_to_DHS_Statistics_DHS-7.pdf), our analytical strategy accounts for the secular trend and for any potential differences in baseline. The analyses for the primary endpoint (ITT, per-protocol) assess risk of under-five mortality over the period of the intervention, and compare the incidence rates of mortality rates across the two arms during this period. Thus, if there are any differences in the under-five mortality rate at baseline, the analytic plan already accounts for this; however, this is not an issue in the trial. For secondary outcomes that differ significantly by arm at baseline, we will use a difference-in-difference estimation strategy to similarly measure differences over time while accounting for this baseline difference, as noted on page 16.
Page 18, line 29: You describe the intervention as -a proactive case detection workflow‖. As noted above please use a standard description for consistency e.g. -door-to-door proactive case detection‖.
Fixed here and throughout.
In the methods section, include further information on how risk of bias will be mitigated. Cochrane EPOC provides guidance for risk of bias for RCTs at https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resourcesforauthors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf 1) mitigation of selection bias by how randomization schemes will be generated; Randomization is described under the section -cluster definition and randomization‖ on page 10 2) mitigation of selection bias by how allocation will be concealed (whether allocation of clusters or controls will be done independently)
Allocation concealment is not a relevant consideration for the trial design of this nature (e.g., villages allocated).
3) how performance bias will be mitigated by whether participants and personnel (i.e. CHWs/others) will be blinded to allocation It is not possible to blind participants and personnel given the nature of the intervention. 4) how performance bias will be mitigated by whether assessors will be blinded to allocation Trial statisticians are blinded to allocation. This is noted on page 10 in the description of the cluster randomization.
5) how attrition bias will be mitigated by mitigating / managing incomplete outcome data Page 14 describes how -surveyors will attempt to contact each eligible woman up to three additional times if she is absent at the first visit‖. On page 13 we add how the survey is designed in Open Data Kit, allowing for real-time quality completeness control on data entry.
We have detailed procedures for handling missing data for primary and secondary endpoints. Four pieces of information are required to estimate our primary endpoint, under-five mortality: date of birth, date of death if applicable, date of survey, and vital status at interview. Date of survey information is complete for all households interviewed. If a child has a missing vital status, the study team will attempt to verify the vital status at the next household survey; otherwise, the child will be dropped from analysis. We will follow the procedures for dealing with missing date of birth/death data set out by the Demographic and Health Surveys. These are described in detail in the Guide to DHS Statistics (https://www.dhsprogram.com/pubs/pdf/DHSG1/Guide_to_DHS_Statistics_DHS-7.pdf). This is described on page 15-16 in the description of the primary endpoint analysis.
If 10% or fewer observations have missing secondary outcome data, we will drop observations from analysis. The 10% threshold is used because this was the assumption for power calculations. If more than 10% of observations are missing outcome data, we will determine sample weights and apply those weights to estimates derived from the sample of observations with complete data. This is described on page 16-17 in the description of secondary endpoints. 6) how reporting bias will be mitigated by mitigating selective reporting Reporting bias is mitigated by publishing the trial protocol. Primary and secondary outcomes are clearly defined on page 10-12. 7) how you will mitigate risk of bias from imbalance in baseline outcomes (including any procedures needed in analysis to adjust for unforeseen imbalances if baseline has not been conducted) Though we find no baseline difference in the under-five mortality rate across arms (primary endpoint), our analytical strategy accounts for the secular trend and for any potential differences in baseline. The analyses for the primary endpoint (ITT, per-protocol) assess risk of under-five mortality over the period of the intervention, and compare the incidence rates of mortality rates across the two arms during this period. For secondary outcomes that differ significantly by arm at baseline, we will use a difference-in-difference estimation strategy to similarly measure differences over time while accounting for this baseline difference. 8) how you will mitigate risk of bias from imbalance in baseline characteristics (including any procedures needed in analysis to adjust for unforeseen imbalances if baseline has not been conducted)
We have added text on page 16 (-Analysis of primary endpoint‖) to indicate that we will control in the analysis for any individual-level characteristics that are unbalanced at baseline. 9) how you will mitigate risk of bias from contamination Details added on page 10. This is also discussed under the section, Limitations. 
Please leave your comments for the authors below
The stratified randomization had 3 levels (PHC in cluster, PHC 1-5 kilometers from cluster, and PHC > 5 kilometers from cluster), and included 15 total strata: PHC in cluster (1 cluster per health catchment area); PHC 1-5 km from cluster (1 strata including all clusters that met this criteria per health catchment area); PHC>5 km from cluster (1 strata including all clusters that met this criteria per health catchment area). This is detailed in the second paragraph of the -Cluster definition and randomization‖ section. We have also clarified that we are including a covariate for distance to PHC in the primary endpoint analysis (see -Analysis of primary endpoint,‖ page 15-16).
We will conduct a per-protocol analysis for the primary endpoint. The definition of treatment adherence and analytical approach that will be used are detailed on page 17. With regard to multiple hypothesis testing, we have re-evaluated the proposed Bonferroni correction for secondary outcomes and decided to remove this (page 16). Because we do not believe many of the secondary outcomes operate through the same hypothetical pathways (i.e., use of a modern method of family planning vs. receipt of postnatal care for newborns), we agree with the Reviewer and will not use the proposed correction.
The sample size calculation considered each cluster as an observation and the cluster-level outcome was defined as the under-five mortality rate per person-years at risk. A negative binomial model was used to simulate the number of deaths, assuming a three-year prospective study with 10% attrition and a coefficient of variation of 0.29. A total of 137 clusters (69 intervention and 68 control) will detect a relative difference of 25% between groups with ~80% power after 36 months. How is this effect size compared to clinical significance?
The description of the sample size result was not quite correct in the original submission. We have corrected it to: -With these parameters, after 36 months the trial has 81.8% power to find a significant effect at the two-tailed 5% significance level when there is a 25% true relative difference in the under-five mortality incidence between treatment and control arms.‖ In other words, the power describes the probability of being able to detect any effect different from 0, and the primary endpoint hypothesis will declare significance for any non-zero difference no matter how small. The assumed true 25% relative difference represents going from a 3% rate (under 5 mortality rate per person-year) for the control arm [iCCM] , and dropping 25% to a 2.25% rate for the new intervention arm [ProCCM] . Although we do have a lower power to detect differences when the true effect is less than 25% relative difference, we still have some chance to detect smaller differences. Although smaller differences may be clinically relevant, economic and logistical constraints keep us from increasing the cluster size to have very large power for smaller differences.
The Reviewer is correct that the initial sample size calculation was estimated with a cluster-level analysis in mind. However, after this sample size calculation was conducted, the trial team decided to use an individual-level model for several reasons:
1.
A Poisson regression mixed-effects model allows us to estimate an incidence rate ratio, which is more informative in terms of effect size, and necessary for the DSMB to decide whether the trial meets stopping rules in interim analyses.
2.
The sample size required for a cluster-level trial is sufficient for an individual-level analysis.
3.
A Poisson regression mixed-effects analysis allows to control for covariates as necessary, including (1) distance to PHC; (2) child's age, which is important because of the non-constant risk of mortality across early childhood; (3) any covariates on which the arms are not balanced at baseline (sensitivity analyses).
We have clarified that we will use cluster-level random effects in the Poisson mixed-effects models to account for non-independence within clusters (see -Analysis of primary endpoint‖, page 15).
The DSMB will include a chairperson and at least three members external to the study team with expertise in the conduct and analysis of cluster-randomised controlled trials in low-income country settings. They will oversee participant safety and evaluate interim results to determine if the trial should be stopped early. Interim analyses of the primary endpoint (under-five mortality) will be performed at 12 and 24 months, estimated using data from the first and second follow-up household surveys. The DSMB will terminate the study early if a 50% relative difference in under-five mortality is detected after 12 months (statistical significance at p<0.001) or a 35% relative difference in under-five mortality after 24 months (p<0.001), a stopping rule more stringent than Haybittle-Peto stopping rules.
In the case of study termination, all participating villages will receive the care with the condition identified in the superior study arm. This information is added to the paper on page 19-20.
VERSION 2 -REVIEW
REVIEWER
Tanya Doherty South African Medical Research Council REVIEW RETURNED 04-Apr-2019
GENERAL COMMENTS
I am satisfied with the responses to the reviewers comments and revised manuscript. 
REVIEWER
